Echo Therapeutics said that it is planning to introduce its new needle-free continuous glucose monitoring system in the US market in 2013.
The Symphony transdermal continuous glucose monitoring (tCGM) system includes a rechargeable Prelude skin permeation system to remove patient’s outermost layer of dead skin cells where the Symphony biosensor will be attached, reports diabeteshealth.com.
The Symphony biosensor then monitors blood sugar levels and by using wireless technology it sends minute-by-minute readings to remote monitors such as smartphones, computers, or tablets.
Previous clinical studies of Symphony tCGM system has shown accuracy of 94.4%, with a further 2.5 % defined as benign errors.
The company recommends that the Symphony biosensor should be placed on one spot for a maximum of three days before being relocated to another spot.